Stroke Trials Registry

Aptiganel
Cerestat® CNS 1102

Action
Glutamate antagonist, non-competitive NMDA channel blocker

Status
Clinical trials halted. "In September 1997, the CNS announced the discontinuation of its Phase III trial in TBI because a planned interim analysis of the data showed insufficient evidence of positive clinical impact. In December 1997, the CNS announced the discontinuation of its Phase III trial in stroke after an interim analysis of data from more than 620 patients indicated that continuation of the trial was not justified. "

Trial(s)
= Ongoing
= Completed

Aptiganel Acute Stroke Trial

Web Links and Publications

Cambridge NeuroScience Web Site.

Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke.
Stroke 1999 Oct;30(10):2038-42.

Cerestat and other NMDA antagonists in ischemic stroke.
Neurology 1997 Nov;49(5) Suppl 4):S66-S69.

Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers.
Br J Clin Pharmacol 1994 Jul;38(1):33-8

UID: 4